In lung cancer patients, H19 expression is associated with advanced tumor-node-metastasis (TNM) stages, reduced disease-free survival (DFS) and poor prognosis; and in the NSCLC, H19 interacts with microRNA-p21 promoting cancer progression and worse prognosis 73, 74. Here, H19 is linked to neoplasm.